Clinical Trials Logo

Infections clinical trials

View clinical trials related to Infections.

Filter by:

NCT ID: NCT05376670 Completed - Clinical trials for Urinary Tract Infections

Patient Satisfaction and Long-term Safety of Intravesical Aminoglycoside Instillations in UTI Prevention

INSTILMENT
Start date: April 20, 2022
Phase:
Study type: Observational

Antimicrobial prophylactic treatment of recurrent UTI is limited by emerging resistance, antibiotic allergies and intolerances. Intravesical aminoglycoside instillations (IAI) have been shown to reduce recurrence rate, without a short-term decline in kidney function or hearing. Thus far, treatment satisfaction has not yet been assessed, while this may play an important role in treatment adherence and persistence. Moreover, there is no data on the long-term safety of IAI, e.g. regarding the development of (pre)malignant bladder lesions.

NCT ID: NCT05376566 Recruiting - Clinical trials for Central Line-associated Bloodstream Infection (CLABSI)

Hydrochloric Acid Lock Therapy for Central Line-associated Bloodstream Infections

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Aim: This study will test whether treatment of central line-associated bloodstream infections (CLABSI) with hydrochloric acid lock therapy (HALT) can significantly reduce the risk of treatment failure (comprising failure to clear initial infection, relapse of infection, or reinfection) in patients treated for cancer or hematologic diseases. Study design: A multicentre, double-blinded, randomized controlled trial. Patient population: Patients (0-100 y) with cancer or a hematologic disorder and a CLABSI treated at Copenhagen University Hospital, Aarhus University Hospital, or Odense University Hospital, Denmark. Randomization: Patients are equally assigned (1:1) to receive either HALT or placebo (normal saline). In addition to the study intervention, patients in both arms will receive standard systemic antibiotic therapy. Sample size: A target population of 250 patients

NCT ID: NCT05375396 Recruiting - Clinical trials for Microbial Colonization

Microbial Colonization of Dairy Free Oral Probiotics

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the colonization efficacy of probiotic lozenges containing dairy and dairy free probiotic Streptococcus salivarius M18, in healthy adults

NCT ID: NCT05375383 Recruiting - Clinical trials for Microbial Colonization

Microbial Colonization of Oral Probiotics

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the colonization efficacy of probiotic lozenges and powders containing specific prebiotics in healthy adults

NCT ID: NCT05375240 Not yet recruiting - Stroke Clinical Trials

Propranolol on Post Stroke Immune Status and Infection

Start date: June 2022
Phase: Phase 2
Study type: Interventional

Stroke-associated pneumonia (SAP) is one of the important risk factors influencing poor outcomes and death in stroke patients. Over the past two decades, accumulating evidence suggests that post-stroke brain injury mobilizes the adrenergic system, which induces post-stroke immunosuppression and SAP. This study is designed to test the safety and efficacy of an adrenergic β-receptor blocker, propranolol, with or without combination of antibiotics, in reducing SAP in stroke patients. The underlying immune mechanisms will be investigated.

NCT ID: NCT05374980 Completed - Insulin Resistance Clinical Trials

The Effects of Yogurt on Gut Microbiome and Metabolism in H. Pylori.

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Helicobacter pylori is a common pathogen causing upper gastrointestinal diseases including gastric ulcer and gastric cancer. Recent epidemiological findings have also shown that it is also related to colon cancer, metabolic syndrome, gut dysbiosis, glycemic control and insulin resistance. The aim of this study is to investigate whether the gut microbiota and insulin resistance of patients with H. pylori infection are abnormal. In addition, whether drinking fermented milk product with probiotic reduces Helicobacter pylori, improves gut microbiota, and increases butyrate-producing bacteria and insulin resistance.

NCT ID: NCT05374070 Recruiting - Clinical trials for Upper Respiratory Tract Infection

Antiviral Activity of Oral Probiotics

Start date: May 23, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to test saliva samples obtained from healthy human participants for anti-viral activity after they have consumed S. salivarius probiotic in a powder format.

NCT ID: NCT05372068 Recruiting - Diarrhea Clinical Trials

Cement flooRs AnD chiLd hEalth (CRADLE)

Start date: September 24, 2023
Phase: N/A
Study type: Interventional

This randomized trial in rural Bangladesh will measure whether installing concrete floors in households with soil floors reduces child enteric infection. The trial will randomize eligible households to receive concrete household floors or to no intervention and measure effects on child soil-transmitted helminth infection, diarrhea, and other enteric infections. The study will collect longitudinal follow-up measurements at birth and when children are ages 3, 6, 12, 18, and 24 months.

NCT ID: NCT05371561 Completed - COVID-19 Clinical Trials

Effect of PPE on Children's Fear in Dental Office

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

the aim of the current study is to compare the effect of conventional facial PPE as 1)goggles + surgical masks, and 2)face shields + surgical masks versus 3)half-face and 4)full-face reusable respirators; on preoperative child's fear in the dental office.

NCT ID: NCT05369104 Recruiting - Clinical trials for Infection of Total Knee Joint Prosthesis

Phage Therapy in Prosthetic Joint Infection Due to Staphylococcus Aureus Treated With DAIR.

PhagoDAIRI
Start date: June 15, 2022
Phase: Phase 2
Study type: Interventional

Pilot non comparative study assessing the clinical control of infection of DAIR + SAT +NaCl and DAIR + SAT + Phages anti-Staphylococcus aureus in patients with Staphylococcus aureus Prosthetic Joint Infection with an indication of DAIR + SAT.